News|Articles|September 18, 2026

FAQ: What the Endocrine Society’s New Scientific Statement Means for Obesity Treatment

Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.

Highly effective obesity medicines have expanded treatment options faster than researchers have answered questions about patient selection, long-term use, and how to measure success. A new Endocrine Society scientific statement, published in Endocrine Reviews, identifies 6 research priorities spanning obesity biology, treatment response, clinical outcomes, and safety.¹

Related to this article

October 22nd, 2026

Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study

TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.

Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months / image credit: mjh life sciences

October 5th, 2026

Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months in New Study

EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.

September 30th, 2026

CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses

EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.

November 2nd, 2026

Abbott's Amulet 360 Linked to Low Stroke Risk at 1 Year in Late-Breaking Research

Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.

November 2nd, 2026

4 FDA Decisions for Primary Care to Know from October 2026

October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.

October 30th, 2026

New Schizophrenia Treatment Addresses Long-Standing LAI Barriers

Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.

October 29th, 2026

Night Sweats in Midlife Women: A Q&A With Cheryl Cox Kinney, MD

Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.

October 29th, 2026

Menopause Care in Primary Care: Closing Diagnosis and Treatment Gaps

TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.